Human ether-à-go-go-related gene 1 (hERG1)–integrin beta-1 membrane complex (hERG1/β1 complex)

The Human ether-à-go-go-related gene 1 (hERG1)–integrin beta-1 membrane complex is a macromolecular assembly formed by the hERG1 (Kv11.1) potassium channel and the β1 subunit of integrin receptors, specifically on the plasma membrane of various cancer cells (Becchetti et al., 2017). Unlike the hERG1 channel alone, which is critical for cardiac repolarization, this specific complex is absent in healthy cardiac tissue, making it a highly selective target for antineoplastic therapy (Arcangeli & Becchetti, 2015). The complex functions as a signaling hub, often localized in lipid rafts, where it recruits and activates the PI3K/Akt pathway to drive tumor progression, metastasis, and angiogenesis (Duranti et al., 2021b). Targeting the complex with bispecific antibodies, such as scDb-hERG1-β1, has shown promise in preclinical models by dissociating the assembly and inhibiting downstream oncogenic signaling without the cardiotoxic side effects associated with traditional hERG1 blockers (Duranti et al., 2021a). Furthermore, the complex serves as a potent biomarker for aggressive cancer phenotypes and can sensitize tumors to conventional chemotherapeutic agents like gemcitabine and oxaliplatin (Lottini et al., 2023). This unique molecular association provides a therapeutic window to exploit ion channel signaling in oncology while bypassing the safety limitations of systemic channel inhibition.

Other names

hERG1/β1 integrin complexKv11.1/β1 integrin complexKCNH2/ITGB1 complexhERG1-integrin beta1 signaling complex

The complex acts as a signaling hub in lipid rafts, recruiting the p85 subunit of PI3K to activate the Akt pathway. Targeting the complex with bispecific antibodies or lipid raft disruptors dissociates the assembly, inhibiting downstream oncogenic signaling, reducing cell survival, and sensitizing cancer cells to chemotherapy.